In the pharmaceutical manufacturing and global health landscape of 2026, Zidovudine capsules (also known as AZT) are classified as a nucleoside reverse transcriptase inhibitor (NRTI). As a pharmacist and manufacturer at Healthy Life Pharma, I view this molecule as a critical, albeit “second-line” component in modern HIV management.
While newer agents like Dolutegravir have taken the lead in many regimens, Zidovudine remains technically essential for specific clinical protocols, particularly in maternal-fetal health.
1. Primary Therapeutic Indications
Zidovudine capsules are technically indicated for three main purposes:
| Indication | Target Group | Technical Rationale |
| HIV-1 Infection Treatment | Adults and Children | Used in combination with other antiretrovirals to slow disease progression and lower viral load. |
| Perinatal Transmission Prevention | Pregnant Women ($>14$ weeks) | Crosses the placenta effectively to protect the fetus from HIV infection during pregnancy. |
| Post-Exposure Prophylaxis (PEP) | Healthcare/Accidental Exposure | Used (rarely as monotherapy now) to prevent viral integration after a potential exposure. |
2. Mechanism: Viral Chain Termination
Zidovudine is a synthetic analog of the nucleoside thymidine.
The Decoy Effect: HIV’s reverse transcriptase enzyme mistakenly uses Zidovudine instead of natural thymidine to build viral DNA.
Chain Termination: Once incorporated, the azido ($N_3$) group on the Zidovudine molecule prevents the formation of the next phosphodiester linkage.
The Result: The viral DNA chain is “terminated,” effectively stopping the virus from replicating and integrating into the host’s genome.
3. Dosing Configurations for 2026
At our Mumbai facility, we focus on the two standard capsule strengths required for international health tenders:
100 mg Capsules: Primarily used for pediatric dosing and for the high-frequency dosing schedule in pregnant women ($100\text{ mg}$ five times daily).
300 mg Capsules: The standard adult strength, typically taken as one capsule twice daily ($600\text{ mg}$ total per day) in combination with other NRTIs.
The Manufacturer’s Perspective: Technical & Export
From the desk of Nishith Shah (Healthy Life Pharma):
Bioavailability & Form: At Healthy Inc, we prioritize the Capsule form for pediatric populations over tablets because they can be opened and mixed with liquids if the child cannot swallow (though an oral solution is technically preferred for neonates).
Hematologic Monitoring: Correction/Technical Alert: Zidovudine is known to cause bone marrow suppression. As a manufacturer, we must include documentation for our B2B buyers advising on the mandatory monitoring of Complete Blood Counts (CBC) to watch for anemia and neutropenia.
Packaging for Export: We utilize Alu-Alu Cold Form Blistering for all 2026 Zidovudine batches. The molecule is sensitive to photodegradation; our opaque capsule shells and high-barrier packaging ensure stability during long-haul shipping to Africa and SE Asia.